Achieve Life Sciences, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Transformation and Operational Context Transitioned from a clinical development firm to a commercially focused enterprise following the June 2025 NDA submission for cytisinicline. Attributed strong clinical momentum to the ORCA-OL study, which demonstrated safety and tolerability over 52 weeks, addressing long-term treatment concerns. Identified a significant market opportunity in the 6 million COPD smokers in the U.S., where ...